This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Diabetes

Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine); chemokine CX3C motif receptor 1 (CX3CR1)

In vitro and mouse studies suggest fractalkine or agonists of its receptor, CX3CR1, could help treat diabetes. In mice, an anti-fractalkine antibody or knockout of Cx3cr1 decreased glucose tolerance and glucose-stimulated insulin secretion compared with vehicle or no knockout, respectively. In mice, soluble fractalkine increased glucose tolerance and insulin secretion compared with what was seen in Cx3cr1 knockouts. In human islets, fractalkine increased glucose-stimulated insulin secretion compared with no treatment. Next steps could include testing soluble fractalkine in mouse models for diabetes.

SciBX 6(17); doi:10.1038/scibx.2013.414
Published online May 2, 2013

Patent and licensing status unavailable

Lee, Y.S. et al. Cell;
published online April 11, 2013;
doi:10.1016/j.cell.2013.03.001
Contact: Jerrold Olefsky, University of California, San Diego, La Jolla, Calif.
e-mail:
jolefsky@ucsd.edu